Sinopharm Tech Holdings Ltd. (Sinopharm Tech) has filed its Monthly Return for the period ended 31 October 2026, confirming a stable capital structure and full compliance with Hong Kong Stock Exchange public-float requirements.

Authorised Capital Stable • Total authorised share capital stayed at HKD 200.00 million, unchanged since the company’s November 2024 capital reorganisation. • The structure remains split into 12.80 billion ordinary shares and 3.20 billion non-voting convertible preference shares, each with a par value of HKD 0.0125.

Issued Shares Unchanged • Ordinary shares in issue: 633.69 million; no new shares were issued, repurchased, or cancelled during the month. • Treasury shares: nil, unchanged. • The company confirmed that the public float exceeds the 25% threshold required under GEM Rule 17.37B.

Preference Shares and Convertibles • Non-voting convertible preference shares (CPS) outstanding: 1.48 billion, representing a notional amount of HKD 148.02 million. • No CPS conversions occurred in October; up to 1.48 billion ordinary shares remain issuable upon conversion at a HKD 0.10 conversion price.

Employee Share Options • Outstanding options under the 2021 Share Option Scheme total 4.96 million units, exercisable at an adjusted price of HKD 1.00 per share. • No option exercises or cancellations were recorded in October. • The scheme currently allows for a further 12.42 million shares to be issued upon future grants and exercises.

Regulatory Compliance • The company affirmed that all listing rule requirements, statutory filings, and documentation obligations have been met for the reporting period.

Operational Context Sinopharm Tech’s capital reorganisation, approved in August 2024 and effective November 2024, reduced the par value of issued shares and subdivided unissued shares without altering total authorised capital. October 2026 marks a continuation of that steady structure, with no equity dilution and confirmed adherence to public-float standards.